Evidence map›Paper›PMID 41729231›Full record

ReviewRadiologie (Heidelberg, Germany)2026

[Sarcomas : Clinical introduction].

Lars H Lindner

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lars H LindnerZentrum für Knochen- und Weichteiltumoren (SarKUM), LMU Klinikum, Medizinische Klinik III, Marchioninistr. 15, 81377, München, Deutschland. lars.lindner@med.uni-muenchen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcomas are malignant tumors of connective and supporting tissues characterized by substantial biological and clinical heterogeneity. Their optimal treatment requires specialized expertise, particularly in radiological diagnostics. The correct interpretation of imaging procedures represents the first crucial step in treatment planning. Radiologists play a key role by recognizing suspicious findings and initiating early referral to specialized sarcoma centers. Depending on the histological subtype, sarcomas require tailored imaging strategies. A notable example is whole-body magnetic resonance imaging (MRI) for the detection of osseous metastases in myxoid liposarcoma. The assessment of treatment response in the neoadjuvant setting also poses a particular challenge as it is not uncommon for treatment-related imaging changes to mimic tumor progression (pseudoprogression) and must be reliably distinguished from true progression. During follow-up an appropriate balance between oncologic safety, such as early detection of local recurrence or metastases, and minimizing cumulative radiation exposure must be achieved.

Indexed as

SarcomaDisease ProgressionHumansMagnetic Resonance ImagingMultidisciplinary careNeoadjuvant therapyPseudoprogressionSarcoma imagingWhole-body magnetic resonance imaging

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.